  |
 |
        |
 |
 |
 |
 |
     |
|||||||||||||||||||||||||||||||||||
 |
Conference Details : Topics |
  |
Register Online |
 |
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||
© 2006 Primary Care Network
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||
|
Conference Details : Topics |
|
Register Online |
|
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
Overview
Despite a high prevalence in the United States, insomnia remains underdiagnosed and undertreated. Extensive research has identified several factors that contribute to the inadequate treatment of insomnia, including the failure of patients to report insomnia to clinicians and clinician misperceptions about the risks associated with hypnotic medications. This program will address effective strategies for diagnosing and treating patients with insomnia.
Objectives
Identify risk factors, determine appropriate screening tools, and accurately diagnose insomnia
Evaluate current and emerging nonpharmacologic and pharmacologic therapies for acute and chronic insomnia on the basis of efficacy and safety and apply this knowledge/skill with patients
Faculty
Joseph A. Lieberman III, MD, MPH
Associate Editor, Delaware Medical Journal
Professor of Family Medicine, Jefferson Medical College
Philadelphia, PA
David Neubauer, MD
Johns Hopkins Sleep Disorder Center
Parkton, MD
Overview
Symptomatic treatment for menopausal women balances findings from clinical trials, guidelines, practice recommendations, and patient beliefs. Together clinicians will evaluate data and recommend initial treatment and follow up to meet a patient's needs for symptom management.
Objectives
Proactively assess and address menopausal issues with appropriate patients using clinician and patient education resources to improve communication and management of menopausal issues
Consistently apply with confidence the best evidence and up-to-date expert consensus recommendations to the clinical care and peri and menopausal patient
Faculty
Jeffrey P. Levine, MD, MPH
UMDNJ-Robert Wood Johnson Medical School
Piscataway, NJ
Overview
More than 20 million people are affected by diabetes and of this population nearly 65% will suffer early cardiovascular death. To effectively treat diabetes and reduce the risk of a cardiovascular event, glucose levels must be monitored and quickly controlled through changes in intervention, as outlined by the ADA/EASD treatment algorithm. Recent data provided by the National Health and Nutrition Examination Surveys (NHANES) revealed that there is some overall improvement in reaching the appropriate treatment standards, however, with the number of diabetes cases increasing by 1.5 million each year and the recent labeling changes affecting therapeutic options, it is more important than ever to be familiar with the pharmacologic treatment options for type 2 diabetes and the associated cardiovascular risk.
Objectives
Identify the current goals for A1C, blood pressure, and lipid levels set forth by the American Diabetes Association and apply them to the treatment strategies listed on the ADA/EASD algorithm in an effort to choose the best therapeutic option for each individual patient
Assess when patients with type 2 diabetes require cardiovascular risk reduction in addition to glycemic control and develop evidence-based approaches to treatment based on the ADA/EASD algorithm by reviewing adverse events
Faculty
Mandeep Bajaj, MD
Associate Professor
Division of Diabetes, Endocrinology & Metabolism and
Molecular & Cellular Biology
Baylor College of Medicine
Houston, TX
Natasa Janicic-Kahric, MD, PhD
Assistant Professor of Medicine
Division of Endocrinology and Metabolism
Georgetown University Hospital
Washington, DC
Overview
The current use of lipid lowering therapy in clinical practice has fallen short of the recommendations of national guidelines. Clearly, not an easy venture when treating patients with dyslipidemia, many with multiple risk factors and many with resulting coronary events that may be preventable if patients were treated aggressively to meet the NCEP-ATP lll goals. This presentation will address the clinical challenges of goal attainment (lack of compliance, aggressive treatment by clinicians, not leaving patients 15 points from goals), and provide clinicians with the pathways and knowledge to help attain their patients to goal.
Objectives
Describe at least two challenges in treating dyslipidemia to NCEP-ATP III goals, implement strategies that will help to assess CHD risk accurately, and get patients to targeted goals
Identify patients at increased risk for cardiovascular events and develop a treatment plan with at least 2 lipid lowering strategies, including the use of multiple therapies, which will help these patients achieve guideline-based targets taking into consideration current lifestyle and pharmacologic treatment options available thus reducing overall cardiovascular risk
Faculty
Robert P. Giugliano, MD, SM
Assistant Professor in Medicine
Harvard Medical School
Boston, MA
Albert Levy, MD, FAAFP
Assistant Clinical Professor Medicine
Mount Sinai School of Medicine
New York, NY
Overview
Allergic rhinitis (AR) is the most common allergic condition in the US, affecting nearly 40 million people. Although AR is associated with significant comorbidities, current therapies have proven only modestly successful. Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Health Care Professional will provide primary care physicians with practical, evidence-based solutions to the challenges of managing AR, with particular emphasis on finding effective treatments and ensuring patient compliance. Two nationally recognized allergy/immunology experts will lead each 75-minute presentation with 60 minutes of didactic lectures and case history presentation, and a 15-minute question-and-answer session. Interactive discussion and a dynamic audience response system will also be integrated into the session.
Objectives
Describe key clinical characteristics of allergic rhinitis, its associated comorbidities, and its impact on patient health and quality of life
Identify barriers to treatment success of allergic rhinitis (treatment-related, physician-related, and patient-related barriers) and adequate control of symptoms, and devise strategies for overcoming those barriers
Faculty
David I. Bernstein, MD
Professor of Clinical Medicine and Environmental Health
University of Cincinnati
Cincinnati, OH
Mark Lee Corbett, MD
University of Louisville
Louisville, KY
Overview
Chronic Constipation is a multi-symptom gastrointestinal motility disorder that negatively impacts the lives of approximately 33 million Americans. Due to the overlap in symptoms reported by patients with irritable bowel syndrome-constipation and chronic constipation, clinicians often find it challenging to differentiate between the two. With a changing landscape of therapeutic options available, it is imperative that clinicians be able to establish and accurate diagnosis so the proper foundation is provided for determining initial therapy and developing a treatment plan.
Objectives
Differentiate chronic constipation from other functional bowel disorders
Identify the therapies that can be used to treat chronic constipation and other functional bowel disorders
Faculty
Lin Chang, MD
Co-Director
Associate Professor of Medicine
Division of Digestive Diseases
Center for Neurovisceral Sciences & Women's Health
David Geffen School of Medicine UCLA
Los Angeles, CA
Brooks D. Cash, MD, FACP, FACG
Chief, Gastroenterology Division & Colon Health Initiative
National Naval Medical Center
Associate Professor of Medicine
Uniformed Services University of the Health Sciences
Bethesda, MD
Overview
Rheumatoid arthritis (RA) is a complex immunologic and chronic inflammatory disease that affects more than 2 million people in the United States. Characterized by inflammation of the joints, periarticular bone resorption and cartilage destruction, RA is also an inherently aggressive, systemic disease that leaves patients vulnerable to comorbidities such as cardiovascular disease, osteoporosis, lymphoma, infection, and stroke. While primary care clinicians may not directly treat the disease long term, they are the first to come in contact with potential RA patients. Therefore it is important for all clinicians to be aware of the necessary steps in RA diagnostic and treatment modalities.
Objectives
Identify 3 early warning signs of rheumatoid arthritis (RA)
Describe current and evolving treatment options for RA, and be alert to monitoring and side effects related to these therapies
Faculty
Kevin Latinis, MD
Allan Gibofsky, MD
Professor of Medicine and Public Health
Weill Medical College of Cornell University Attending
Rheumatologist Hospital for Special Surgery
New York, NY